natgillin/translations-raw huggingface dataset:
Bosutinib exposure was not increased in subjects with mild renal impairment.
Izloženost bosutinibu nije porasla u ispitanika s blagim oštećenjem funkcije bubrega.
Bosutinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity and photoxicity studies.
Bosutinib je procijenjen u ispitivanjima sigurnosne farmakologije, toksičnosti ponovljene doze, genotoksičnosti, reproduktivne toksičnosti i fototoksičnosti.
Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines.
Bosutinib je inhibirao 16 od 18 oblika Bcr-Abl-a rezistentnih na imatinib izraženih u mijeloidnim staničnim linijama miševa.
Bosutinib inhibits the abnormal Bcr-Abl kinase that promotes CML.
Bosutinib inhibira abnormalnu Bcr-Abl kinazu koja pospješuje KML.
Bosutinib should be used with caution in patients who have or may develop prolongation of QT, including those patients taking anti-arrhythmic medicinal products such as amiodarone, disopyramide, procainamide, quinidine and sotalol or other medicinal products that may lead to QT prolongation such as chloroquine, halofantrine, clarithromycin, domperidone, haloperidol, methadone and moxifloxacin (see section 4.4).
Bosutinib se mora oprezno primjenjivati u bolesnika koji imaju ili mogu razviti produljeni QT interval, uključujući bolesnike koji uzimaju antiaritmike kao što su amiodaron, dizopiramid, prokainamid, kinidin i sotalol ili druge lijekove koji mogu dovesti do produljenja QT intervala kao što su klorokin, halofantrin, klaritromicin, domperidon, haloperidol, metadon i moksifloksacin (vidjeti dio 4.4).
Bosutinib treatment reduced the size of CML tumours growing in nude mice and inhibited growth of murine myeloid tumours expressing imatinib-resistant forms of Bcr-Abl.
Liječenje bosutinibom smanjilo je veličinu tumora KML-a u golim miševima i inhibiralo rast mišjih mijeloidnih tumora koji su izrazili oblike Bcr-Abl-a rezistentne na imatinib.
Bosutinib was not carcinogenic in the 2-year rat carcinogenicity study.
Bosutinib nije bio kancerogen u dvogodišnjem ispitivanju kancerogenosti provedenom na štakorima.
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p<0.05).
U 16. tjednu primjene 25 mg alogliptina, samog i u kombinaciji s 30 mg pioglitazona, postižu se u odnosu na placebo značajna smanjenja postprandijalne glukoze i postprandijalnog glukagona uz značajno povećanje postprandijalnih razina aktivnog GLP-1 (p<0,05).
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p<0.05).
U 16. tjednu primjene 25 mg alogliptina, samog i u kombinaciji s 30 mg pioglitazona, postižu se, u odnosu na placebo, značajna smanjenja postprandijalne glukoze i postprandijalnog glukagona uz značajni porast postprandijalnih razina aktivnog GLP-1 (p<0,05).
Both abacavir and dolutegravir are associated with a risk for hypersensitivity reactions (HSR) (see section 4.8), and share some common features such as fever and/or rash with other symptoms indicating multi-organ involvement.
I abakavir i dolutegravir povezuju se s rizikom od reakcija preosjetljivosti (vidjeti dio 4.8) te dijele neke zajedničke značajke, poput vrućice i/ili osipa praćenih drugim simptomima koji upućuju na zahvaćenost većeg broja organa.
Both active substances of Suboxone, buprenorphine and naloxone, are extensively metabolized in the liver, and the plasma levels were found to be higher for both buprenorphine and naloxone in patients with moderate and severe hepatic impairment.
Obje djelatne tvari lijeka Suboxone, buprenorfin i nalokson, opsežno se metaboliziraju u jetrii i utvrđeno je da su njihove izmjerene razine u plazmi više u bolesnika s umjerenim i teškim oštećenjem jetre.
Both adverse reactions and laboratory values have been used to provide frequencies.
Pri određivanju učestalosti u obzir su uzete i nuspojave i laboratorijske vrijednosti.
Both adverse reactions and laboratory values have been used.
Uzimane su u obzir i nuspojave i laboratorijske vrijednosti.
Both anti-TNFα-naive and anti-TNFα-IR Cosentyx-treated patients had a significantly higher ACR 20 response compared to placebo at Week 24, with a slightly higher response in the anti-TNFα-naive group (anti-TNFα-naive: 37%, 64% and 58% for 75 mg, 150 mg and 300 mg, respectively, compared to placebo 15.9%; anti-TNFα-IR: 15%, 30% and 46% for 75 mg, 150 mg and 300 mg, respectively, compared to placebo 14.3%).
I bolesnici koji nisu ranije primali anti-TNFα i anti-TNFα-NO bolesnici liječeni Cosentyxom imali su značajno viši odgovor ACR 20 u usporedbi s placebom u 24. tjednu, uz nešto viši odgovor u skupini koja nije ranije primala anti-TNFα (bez prethodnog primanja anti-TNFα: 37%, 64% odnosno 58% za redom 75 mg, 150 mg odnosno 300 mg, u usporedbi s placebom 15,9%; s neodgovarajućim odgovorom na anti-TNFα: 15%, 30% odnosno 46% za redom 75 mg, 150 mg odnosno 300 mg, u usporedbi s placebom 14,3%).
Both are anti– hypertensive medicines that have been available separately in the European Union (EU) since the mid- 1990s.
Obje su antihipertenzivni lijekovi koji su u Europskoj uniji (EU) dostupni zasebno od sredine 1990-ih.
Both are anti–hypertensive medicines that have been available separately in the European Union (EU) since the mid-1990s.
Obje tvari su antihipertenzivni lijekovi koji su zasebno dostupni u Europskoj uniji (EU) od sredine 1990-tih godina.
Both are not included in the package.
Ni epruvete niti vrećice za izdahnuti zrak nisu uključene u pakiranje.
Both clomipramine and desmethylclomipramine contribute to the effects of Clomicalm: clomipramine is a potent and selective 5-HT reuptake inhibitor while desmethylclomipramine is a potent and selective noradrenaline reuptake inhibitor.
I klomipramin i desmetilklomipramin pridonose učincima Clomicalma: klomipramin je potentni i selektivni inhibitor ponovne pohrane 5-HT, dok je desmetilklomipramin potentni i selektivni inhibitor ponovne pohrane noradrenalina.
Both combinations were taken with efavirenz (another antiviral medicine) by patients with HIV-1 infection.
Bolesnici s infekcijom virusom HIV-1 obje su kombinacije uzimali zajedno s efavirenzom (drugim antivirusnim lijekom).
Both components are mixed together just before your child receives the injection.
Obje komponente se moraju pomiješati prije nego li Vaše dijete primi cjepivo.
Both components of this medicinal product should be infused using a variable rate, infusion pump with a subcutaneous needle set that is at least 24 gauge with the ability to titrate flow up and down.
Obje komponente ovog lijeka moraju se dati infuzijom uz pomoć infuzijske pumpe promjenljive brzine sa supkutanom iglom od najmanje 24 G koja može titrirati protok prema gore i dolje.
Both diabetic ketoacidosis and hyperosmolar hyperglycaemia have been described, which generally respond to administration of exogenous insulin.
Opisane su i dijabetička ketoacidoza i hiperosmolarna hiperglikemija, koje većinom reagiraju na primjenu egzogenog inzulina.
Both dibotermin alfa and bovine Type I collagen have been found to elicit immune responses in patients.
Otkriveno je da i dibotermin alfa i goveđi kolagen tipa I izazivaju imunološke odgovore u bolesnika.
Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate.
Glikozidi digitalisa i beta-blokatori usporavaju atrioventrikularnu provodljivost i smanjuju otkucaje srca.
Both documents are to be used as part of an educational plan aiming to minimise risks of medication errors, risk of thromboembolic events due to increased levels of non-proteolytically activated rFXIII in connection with incorrect storage, and risk of off-label use for treatment of breakthrough bleeding.
Oba dokumenta treba koristiti kao dio edukacijskog plana izrađenog kako bi se smanjio rizik od medikacijske pogreške, rizik od tromboembolijskih incidenata zbog povećane razine neproteolitički aktiviranog rFXIII zbog nepravilnog čuvanja te zbog rizika vezanog za primjenu lijeka u neodobrenoj indikaciji za liječenje probojnog krvarenja.
Both dose strengths of dabigatran etexilate had also a statistically significant lower total bleed rate.
Obje doze dabigatraneteksilata imale su statistički značajno nižu ukupno stopu krvarenja.
Both drugs are CYP3A4 inhibitors and may increase the plasma concentration of saquinavir.
Streptograminski antibiotici poput kvinupristina/dalfopristina inhibiraju CYP3A4.
Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Emtricitabin i tenofovir djeluju na sličan način onemogućujući djelovanje reverzne transkriptaze, enzima koji proizvodi HIV koji mu omogućuje da zarazi stanice i proizvodi više virusa.
Both emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA polymerases and there was no evidence of toxicity to mitochondria in vitro and in vivo.
I emtricitabin trifosfat i tenofovir difosfat su slabi inhibitori DNK polimeraza u sisavaca, a toksičnost po mitohondrije nije dokazana in vitro i in vivo.
Both endothelial cell damage and prothrombotic-hypofibrinolytic state are critical factors in the pathophysiology of this disease.
I oštećenje endotelnih stanica i protrombotsko-hipofibrinolitičko stanje kritični su čimbenici u patofiziologiji ove bolesti.
Both field studies showed that vaccination with Coliprotec F4 reduced the number of pigs with moderate to severe diarrhoea.
Oba terenska ispitivanja su pokazala da je cjepivo s Coliprotec F4 smanjilo broj svinja s umjerenim do ozbiljnim proljevom.
Both fipronil and amitraz kill adult parasites while (S)-methoprene kills parasites at the egg or larval stage.
Fipronil i amitraz ubijaju odrasle parazite dok (S)- metopren ubija parazite u stadiju jajašca ili ličinke.
Both groups showed a robust response to the booster dose of Menveo at one month after vaccination (100% of subjects had hSBA ≥ 1:8 across serogroups) and this response largely persisted through 2 years after the booster dose for serogroups C, W135 and Y (with 87% to 100% of subjects with hSBA ≥ 1:8 across serogroups).
Obje grupe pokazale su snažan odgovor na docjepljivanje cjepivom Menveo jedan mjesec nakon cijepljenja (100% ispitanika imalo je hSBA ≥ 1:8 za sve serogrupe) i taj odgovor je većinom ostao postojan tijekom 2 godine nakon docjepljivanja za serogrupe C, W135 i Y (87% do 100% ispitanika imalo je hSBA ≥ 1:8 za sve serogrupe).
Both hoarseness and incidence of mouth and throat candidiasis may be relieved by rinsing the mouth with water and spitting the water out and/or brushing the teeth after using the product.
I promuklost i incidencija kandidijaze usta i grla mogu se smanjiti tako da se nakon primjene lijeka usta isperu vodom i ta voda ispljune i/ili da se operu zubi.
Both hoarseness and the incidence of candidiasis of the mouth and throat may be relieved by rinsing the mouth with water and spitting the water out and/or brushing the teeth after using the product.
I promuklost i incidencija kandidijaze usta i grla mogu se smanjiti tako da se nakon primjene tog lijeka usta isperu vodom i ta voda ispljune i/ili da se operu zubi.
Both in healthy subjects and PAH patients, exposure at steady state to the active metabolite is approximately 3- to 4-fold higher than to the parent compound.
I u zdravih ispitanika i u bolesnika s PAH-om, izloženost aktivnom metabolitu u stanju dinamičke ravnoteže je približno 3-4 puta veća od izloženosti izvornom lijeku.
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to toremifene, in the form of QT prolongation.
I u pretkliničkim ispitivanjima te u ispitivanjima na ljudima, uočene su promjene u elektrofiziologiji srca nakon izloženosti toremifenu, u obliku produljenja QT segmenta.
Both inborn dieseases are extremely rare, with a prevalence in Europe of about 3 to 5 patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency per 10 million inhabitants, and an estimated ten-fold lower prevalence for Δ4-3-Oxosteroid-5β-reductase deficiency.
Obje prirođene bolesti iznimno su rijetke s prevalencijom u Europi od otprilike 3 do 5 bolesnika s deficijencijom 3β-hidroksiΔ5-C27-steroid oksidoreduktaze na 10 milijuna stanovnika i procijenjenom deseterostruko manjom prevalencijom deficijencije Δ4-3-oksosteroid-5β-reduktaze.
Both key secondary endpoints were also met.
Oba ključna sekundarna ishoda također su ispunjena.
Both medicinal products are metabolised intracellularly to their active moieties, lamivudine 5’-triphosphate (TP) and zidovudine 5’-TP respectively.
Oba se lijeka u stanicama metaboliziraju u svoje aktivne oblike, lamivudin 5'–trifosfat (TP) i zidovudin 5'-TP.
Both medicines were given as one drop in the affected eye once a day, in the evening.
Doza za oba lijeka bila je jedna kapljica u zahvaćeno oko koja se davala navečer.
Both medicines were given in combination with daily prednisone or prednisolone.
Oba lijeka su primjenjena u kombinaciji s dnevnim prednizonom ili prednizolonom.
Both men and women receiving Bortezomib Accord must use effective contraception during and for up to 3 months after treatment.
I muškarci i žene moraju koristiti djelotvorna kontracepcijska sredstva dok su na liječenju Bortezomib Accordom, te do 3 mjeseca nakon liječenja.
Both metabolites appeared slowly in plasma after administration of TAGRISSO to patients, with a median (min-max) tmax of 24 (4-72) and 24 (6-72) hours, respectively.
Oba su se metabolita pojavila sporo u plazmi bolesnika nakon primjene lijeka TAGRISSO, uz medijan (min- max) tmax od 24 (4-72) odnosno 24 (6-72) sata.
Both metabolites, are further metabolised forming a common hydroxylated acid.
Oba metabolita dalje se metaboliziraju i tvore zajedničku hidroksilnu kiselinu.
Both metabolites, M-2 and M-5, exhibit non-linear accumulation, which might be caused by entero- hepatic recycling or saturation of the UGT1A9 pathway.
Oba metabolita, M-2 i M-5 iskazuju nelinearnu akumulaciju, koja može biti uzrokovana enterohepatičkom recirkulacijom ili zasićenjem metaboličkog mehanizma UGT1A9.
Both might interfere with the Helicobacter pylori status.
Obje vrste terapije mogu interferirati sa statusom bakterije Helicobacter pylori.
Both nivolumab-containing arms demonstrated a significant PFS benefit and greater ORR compared with ipilimumab alone, and the observed PFS and ORR results at 12 months of follow-up were consistently demonstrated across subgroups of patients including baseline ECOG performance status, BRAF status, M stage, age, history of brain metastases, and baseline LDH level.
Obje skupine čija je terapija uključivala nivolumab ostvarile su značajne korisne učinke na PFS i veći ORR u odnosu na monoterapiju ipilimumabom, a opaženi rezultati za PFS i ORR nakon 12 mjeseci praćenja bili su dosljedno ostvareni u svim podskupinama bolesnika, uključujući početni funkcionalni ECOG status, BRAF status, metastatski stadij, dob, metastaze u mozgu u anamnezi i početnu vrijednost LDH.
Both of these active ingredients can cause a serious allergic reaction known as a hypersensitivity reaction, which can be life threatening in people who continue to take abacavir-containing products.
Obje te djelatne tvari mogu uzrokovati ozbiljnu alergijsku reakciju koja se naziva reakcijom preosjetljivosti, a može ugroziti život osoba koje nastave uzimati lijekove koji sadrže abakavir.
Both of these active substances are antiretroviral medicines which are used to treat HIV infection.
Obje su djelatne tvari antiretrovirusni lijekovi koji se upotrebljavaju za liječenje HIV infekcije.
Both of these substances help to control high blood pressure (hypertension).
Obje tvari pomažu u kontroli povišenog krvnog tlaka (hipertenzije).
Both of these substances help to control your high blood pressure:
Obje ove tvari pomažu u kontroli visokog krvnog tlaka.
Both patient populations presented a median age of 68.5 years with comparable male to female ratio.
Obje populacije bolesnika imale su medijan dobi od 68,5 godina s usporedivim omjerom muškaraca i žena.
Both patients and healthcare professionals should adhere to any safety instructions provided with the light source used during therapy.
I bolesnik i zdravstveni djelatnici moraju se tijekom liječenja pridržavati svih sigurnosnih uputa priloženih uz primijenjeni izvor svjetlosti.
Both phase 3 studiesexcluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or NYHA Class III or IV heart failure (study 301) or Class II to IV heart failure (study 302) or cardiac ejection fraction measurement of < 50%.
Ni u jedno od dva ispitivanja faze III nisu uključivani bolesnici s nekontroliranom hipertenzijom, klinički značajnom bolešću srca koja se manifestirala infarktom miokarda ili arterijskim trombotičkim događajima u prethodnih 6 mjeseci, bolesnici s teškom ili nestabilnom anginom te bolesnici sa zatajivanjem srca NYHA stupnja III i IV (ispitivanje 301) ili zatajenjem srca stupnja II do IV (ispitivanje 302) ili ejekcijskom frakcijom srca < 50%.
Both primary and secondary hyperparathyroidism can cause loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.
Oba, i primarni i sekundarni hiperparatireoidizam mogu uzrokuvati gubitak kalcija iz kosti, što može biti uzrok bola u kostima i prijeloma, poremećaja krvi i oštećenja srčanih krvnih žila, nastanak bubrežnih kamenaca, psihičkih poremećaja i kome.
Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.
Oba, i primarni i sekundarni hiperparatireoidizam mogu uzrokuvati gubitak kalcija iz kosti, što može biti uzrok bolova u kostima i prijeloma, poremećaja krvi i oštećenja srčanih krvnih žila, nastanak bubrežnih kamenaca, psihičkih poremećaja i kome.
Both rash and diarrhoea resulted in discontinuation of Tarceva in 1% of patients.
Sveukupno su osip i proljev doveli do prekida liječenja lijekom Tarceva u 1% bolesnika.
Both regimens were administered once every 3 weeks for 6 cycles.
Oba kemoterapijska protokola primjenjivala su se svaka tri tjedna tijekom 6 ciklusa.
Both regimens were administered once every 3 weeks for 6 cycles.
Oba kemoterapijska protokola primjenjivala su se svaka tri tjedna, tijekom 6 ciklusa.
Both regimens were well- tolerated by these patients.
Ovi su bolesnici dobro podnosili oba načina doziranja.
Both saxagliptin and dapagliflozin can individually increase the risk of hypoglycaemia when combined with an insulin secretagogue.
I saksagliptin i dapagliflozin mogu svaki zasebno povećati rizik od hipoglikemije kada se primjenjuju u kombinaciji s inzulinskim sekretagogom.
Both sexually active men and women of childbearing potential should use effective methods of contraception during treatment.
Muškarci i žene u reproduktivnoj dobi koji su spolno aktivni trebaju koristiti učinkovite metode kontracepcije tijekom liječenja.
Both sexually active men and women should use effective methods of contraception during treatment and for at least three months following cessation of treatment.
Za vrijeme trajanja liječenja, te barem tri mjeseca nakon završetka liječenja i spolno aktivni muškarci i spolno aktivne žene moraju primjenjivati učinkovite metode kontracepcije.
Both sofosbuvir and velpatasvir were fully active against substitutions associated with resistance to other classes of direct acting antivirals with different mechanisms of actions, such as NS5B non-nucleoside inhibitors and NS3 protease inhibitors.
I sofosbuvir i velpatasvir su bili potpuno djelatni protiv supstitucija povezanih s rezistencijom na druge skupine antivirotika koji djeluju direktno s različitim mehanizmima djelovanja, kao što su NS5B nenukleozidni inhibitori i NS3 inhibitori proteaze.
Both sows and gilts (and their piglets) were investigated in these studies.
Krmače i nazimice (i njihova prasad) ispitani su u ovim ispitivanjima.
Both studies also looked at the maintenance of the effect in the second year of treatment, during which the number of injections and the time between injections were adjusted depending on the vision and changes within the eye.
Oba su ispitivanja istražila održavanje djelovanja u drugoj godini nakon liječenja, tijekom kojeg je broj injekcija i vrijeme između injekcija prilagođeno ovisno o vidu i promjenama unutar oka.
Both studies compared Intelence with placebo (a dummy treatment), when they were taken with boosted darunavir (a protease inhibitor) and at least two other anti-HIV medicines that were chosen for each patient as they had the best chances of reducing the levels of HIV in the blood.
Oba su ispitivanja usporedila Intelence s placebom (lažnim liječenjem), u slučaju kada su uzimani s pojačanim darunavirom (inhibitorom proteaze) i najmanje dva druga lijeka protiv HIV-a koji su bili odabrani za svakog bolesnika s obzirom da su imali najbolje izglede za snižavanje razina HIV-a u krvi.
Both studies compared the effects of Aptivus with those of another protease inhibitor that was chosen on the basis of the patient’s previous treatments and predicted response.
Oba su ispitivanja usporedila djelovanje lijeka Aptivus s djelovanjem drugih inhibitora proteaze koji su odabrani na temelju prethodnog liječenja bolesnika i predviđenog odgovora.
Both studies compared Vidaza with conventional care (treatment chosen for each patient based on local practice and the patient’s condition).
U obama je ispitivanjima lijek Vidaza uspoređen s konvencionalnom terapijom (terapija odabrana za svakog bolesnika na osnovi lokalne prakse i stanja bolesnika).
Both studies demonstrated a statistically significant increase in growth rate compared to placebo over the first year (9.1-10.9 cm/year vs 6.2-6.6 cm/year), which decreased slightly in the second year (7.4-7.9 cm/year vs 5.5-6.6 cm/year).
Oba ispitivanja pokazala su statistički značajan porast stope rasta u usporedbi s placebom tijekom prve godine (9,1 – 10,9 cm/godinu naspram 6,2-6,6 cm/godinu) što lagano opada u drugoj godini (7,4-7,9 cm/godinu naspram 5,5-6,6 cm/godinu).
Both studies showed the vaccine to be effective in reducing death.
Oba su ispitivanja pokazala da je cjepivo djelotvorno u smanjenju smrtnosti.
Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE.
Oba ispitivanja bila su randomizirana, dvostruko slijepa, multinacionalna, s paralelnim skupinama, u bolesnika sa simptomatskom proksimalnom dubokom venskom trombozom ili simptomatskom plućnom embolijom.
both studies, the main measure of effectiveness was the number of patients with a complete or partial response to treatment.
U oba ispitivanja, glavna mjera djelotvornosti bio je broj bolesnika s potpunim ili djelomičnim odgovorom na liječenje.
Both the 0.5 ml and 1 ml vials contain an overfill to allow the withdrawal of 50 mg or 100 mg respectively.
Bočice od 0,5 ml i 1 ml sadrže suvišak kako bi se omogućilo izvlačenje 50 mg odnosno 100 mg lijeka.
Both the events of hypertrophic scarring were medically confirmed; in one case the scar was persistent after 12 months.
U nekim slučajevima promjene se nisu povukle ni više od godinu dana nakon liječenja.
Both the invented name Kadcyla and its full non-proprietary name (trastuzumab emtansine) should be used and confirmed when prescribing, preparing the infusion solution and administering Kadcyla to patients.
Prilikom propisivanja, pripremanja otopine za infuziju i primjene lijeka Kadcyla bolesnicima, mora se koristiti i provjeriti kako zaštićeno ime Kadcyla, tako i puni međunarodni nezaštićeni naziv (trastuzumab emtanzin).
Both the liver and the kidney have been shown to metabolise IGF-1.
Pokazano je da i jetra i bubrezi metaboliziraju IGF-1.